In a press release, the Andalusian Regional Government highlights the joint commitment of both entities to continue advancing in the promotion of R&D&I, following the meeting […]

Of the 1,944 clinical trials authorised in the European Union through the new European Information System, Spanish centres participated in 845, or 43% of the total. […]

The European Medicines Agency has thus identified nine oncology approvals for 2023. The arrival of new treatments is directly linked to the pharmaceutical industry’s commitment to […]

The Technological Platform for Innovative Medicines – whose Coordination Committee is made up of 10 representatives from the pharmaceutical industry and 10 representatives from public research […]

Farmaindustria welcomes the presentation by the Ministry of Health of the harmonised catalogue of genetic tests for the whole country. For this catalogue to become a […]

The US expert unpacked the data from his study on the relationship between pharmaceutical innovation and cancer mortality in Spain between 1999 and 2016 in a […]

“We are the industrial area that invests the most in R&D, a productive and exporting engine”. larazon.es Developing and producing new medicines for society is both […]

The working group led by Farmaindustria holds a new meeting, with the participation of two new pharmaceutical companies. Farmaindustria.es The drive for clinical research in Primary […]

Of the €1.395 billion registered in 2022, 60% was devoted to clinical trial development. One out of every eight euros is already spent on basic and […]

Farmaindustria participates in the Medical Oncology, Haematology and Oncohaematology Pharmacy Congress ‘Building Bridges’, where data management in biomedical research was discussed. Farmaindustria.es “The proposed Regulation for […]